At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Nov 9, 2026 at 16:05 ET
Zymeworks reported Q3 2026 revenue of $256.5M (vs consensus $221.0M) and GAAP diluted EPS of $2.28, driven by a $250M milestone from Jazz for Ziihera's FDA approval. The company raised full-year 2026 revenue guidance to $337M-$351M and adjusted EBITDA to $176M-$190M, reflecting the milestone and Theravance Biopharma acquisition.
- Q3 2026 total revenue $256.5M vs $27.6M YoY, including $250M Ziihera milestone
- GAAP diluted EPS $2.28 vs $(0.26) YoY
- 2026 revenue guidance raised to $337M-$351M (prior $278M-$292M)
- 2026 adjusted EBITDA guidance raised to $176M-$190M (prior $114M-$128M)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access